Lungs News and Research

RSS

1.3 million cancer deaths in 2012 in the EU: Report

New research released this Wednesday shows that almost 1.3 million people will die of cancer in the European Union this year, but death rates from the disease are on a steady decline.

1 Mar 2012

Judge overrules proposed graphic cigarette labels

A Washington judge overruled the federal mandate requiring tobacco companies to place graphic images on their products warning of the dangers of smoking. The judge said the requirements were a violation of free speech.

1 Mar 2012

New robotic surgical system can treat early-stage lung cancer

In a Canadian first, thoracic surgeons at Toronto General Hospital, University Health Network used a robotic surgical system to treat early-stage lung cancer by removing the cancer, along with a lobe of the lung. The use of this system improves outcomes after surgery and will expand the numbers of patients who can benefit from this type of minimally invasive surgical treatment.

1 Mar 2012

Parasitic worms could offer new treatment hope for MS patients

Parasitic worms could offer a new treatment hope for patients suffering from the autoimmune disease multiple sclerosis, scientists believe.

1 Mar 2012

U-M summit to focus on shortage of medical technologies for children

The University of Michigan is hosting the three-day summit that will focus attention on the widespread shortage of medical technologies to help sick children.

From Medtronic 1 Mar 2012

NKT cells may reduce monocytes accumulation, prevent lung injury in severe flu

While some scientists report engineering a super virulent strain of the H5N1 influenza virus, which could potentially wipe out a significant percentage of the human population, another group of researchers from the United Kingdom now reports a discovery that may one day help mitigate the deadly effects of all flu strains.

1 Mar 2012

Inhaled interferon-gamma may effectively treat IPF

Inhaled interferon-gamma may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a chronic and progressive form of lung disease caused by excessive formation of fibrotic, or scar tissue, in the lungs, according to an article published in Journal of Aerosol Medicine and Pulmonary Drug Delivery, a peer-reviewed journal from Mary Ann Liebert, Inc.

1 Mar 2012

Springer adds 6 new quarterly clinical review journals to medicine portfolio

Springer is adding six new quarterly clinical review journals to its existing medicine portfolio in March 2012. These new journals will expand the publisher's medical specialty coverage, focusing on dermatology, geriatrics/gerontology, nutrition, obesity, obstetrics/gynecology and respiratory care.

29 Feb 2012

New NOSH-aspirin appears more effective against cancer

Scientists have combined two new "designer" forms of aspirin into a hybrid substance that appears more effective than either of its forebears in controlling the growth of several forms of cancer in laboratory tests. Their report on the new NOSH-aspirin, so named because it releases nitric oxide (NO) and hydrogen sulfide (H2S), appears in the journal ACS Medicinal Chemistry Letters.

29 Feb 2012

Sleeping pills may raise risk of death: Study

According to a U.S. study, people who take certain prescription sleeping pills even once in a while may be up to five times more susceptible to early death. In the U.S., an estimated six per cent to 10 per cent of adults used the drugs in 2010.

29 Feb 2012

Cold air can trigger coronary events

People with heart disease may not be able to compensate for their bodies' higher demand for oxygen when inhaling cold air, according to Penn State researchers, making snow shoveling and other activities dangerous for some.

29 Feb 2012

NJH to improve asthma care in Colorado's San Luis Valley

National Jewish Health has received a grant for $950,308 from GlaxoSmithKline to improve care of asthma patients in Colorado's San Luis Valley with educational materials for patients and hands-on training for primary health care teams.

29 Feb 2012

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

Nurses play a key role in alleviating cancer patients' concerns

Often faced with overwhelming anxiety, patients newly diagnosed with lung cancer can find themselves in distress, and new research recommends nurses play a key role in alleviating concerns, leading to a better quality of life for patients.

29 Feb 2012

XL888 inhibitor can prevent vemurafenib resistance in melanoma patients

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma.

29 Feb 2012

DTMI, Bristol-Myers Squibb partner to broaden interactions

Bristol-Myers Squibb Company and Duke Translational Medicine Institute (DTMI) today announced the formation of a strategic relationship to broaden interactions between the two organizations.

28 Feb 2012

Aurora-A protein blocks proper functioning of tumor-suppressor p73

A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.

28 Feb 2012

New protocol decreases sternum infections in kids by 61%

A two-year effort to prevent infections in children healing from cardiac surgery reduced sternum infections by 61 percent, a San Antonio researcher announced at the Cardiology 2012 conference Feb. 23 in Orlando, Fla.

28 Feb 2012

Enrollment complete in Ikaria iNO Pivotal Phase III trial for BPD

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).

27 Feb 2012

Biodesix, Kadmon enter Phase 3 non-small cell lung cancer study collaboration

Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix' VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon's KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.

27 Feb 2012